{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:41:01Z","timestamp":1761100861073},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.critrevonc.2005.10.001","type":"journal-article","created":{"date-parts":[[2006,6,5]],"date-time":"2006-06-05T18:54:15Z","timestamp":1149533655000},"page":"257-265","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of mantle cell lymphoma: Current approach and future directions"],"prefix":"10.1016","volume":"58","author":[{"given":"Joshua","family":"Brody","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"July (7)","key":"10.1016\/j.critrevonc.2005.10.001_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"September (5)","key":"10.1016\/j.critrevonc.2005.10.001_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European\u2013American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2005.10.001_bib3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: a population-based clinical study","volume":"14","author":"Velders","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib4","doi-asserted-by":"crossref","unstructured":"The Non-Hodgkin's Lymphoma Classification Project. The A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89(June (11)):3909\u201318.","DOI":"10.1182\/blood.V89.11.3909"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2005.10.001_bib5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2005.10.001_bib6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1997.15.4.1664","article-title":"Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants","volume":"15","author":"Majlis","year":"1997","journal-title":"J Clin Oncol"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2005.10.001_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/oxfordjournals.annonc.a059154","article-title":"Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period","volume":"6","author":"Norton","year":"1995","journal-title":"Ann Oncol"},{"issue":"January (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","article-title":"Molecular basis of mantle cell lymphoma","volume":"124","author":"Bertoni","year":"2004","journal-title":"Br J Haematol"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2005.10.001_bib9","first-page":"1127","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"issue":"June (12)","key":"10.1016\/j.critrevonc.2005.10.001_bib10","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"issue":"February (3)","key":"10.1016\/j.critrevonc.2005.10.001_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2005.10.001_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.leu.2403387","article-title":"Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome","volume":"18","author":"Schrader","year":"2004","journal-title":"Leukemia"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2005.10.001_bib13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/00000478-199609000-00009","article-title":"Clinicopathologic study of PRAD1\/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma A distinct molecular pathologic entity","volume":"20","author":"Yatabe","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"February (3)","key":"10.1016\/j.critrevonc.2005.10.001_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2141.2003.04121.x","article-title":"Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma","volume":"120","author":"Nagy","year":"2003","journal-title":"Br J Haematol"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2005.10.001_bib15","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","article-title":"Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma","volume":"101","author":"Walsh","year":"2003","journal-title":"Blood"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2005.10.001_bib17","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"issue":"September\u2013October (5)","key":"10.1016\/j.critrevonc.2005.10.001_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2005.10.001_bib19","first-page":"836","article-title":"Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group","volume":"10","author":"Unterhalt","year":"1996","journal-title":"Leukemia"},{"issue":"September (1\u20132)","key":"10.1016\/j.critrevonc.2005.10.001_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","article-title":"Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients","volume":"39","author":"Romaguera","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2005.10.001_bib21","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2005.10.001_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2005.10.001_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1008301432453","article-title":"The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"issue":"January (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF02982806","article-title":"Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan","volume":"76","author":"Tobinai","year":"2002","journal-title":"Int J Hematol"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2005.10.001_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Swiss Group for Clinical Cancer Research. Related articles links effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"March (9)","key":"10.1016\/j.critrevonc.2005.10.001_bib28","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"March (5)","key":"10.1016\/j.critrevonc.2005.10.001_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2005.10.001_bib30","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib31","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al., High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;(September) [Epub ahead of print].","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1388.1388","article-title":"Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: a Wisconsin oncology network study","volume":"104","author":"Kahl","year":"2004","journal-title":"Blood"},{"issue":"February (1 Suppl. 2)","key":"10.1016\/j.critrevonc.2005.10.001_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/sonc.2002.30143","article-title":"Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma","volume":"29","author":"Mangel","year":"2002","journal-title":"Semin Oncol."},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2005.10.001_bib34","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2005.10.001_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008278605751","article-title":"Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma","volume":"8","author":"Ketterer","year":"1997","journal-title":"Ann Oncol"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2005.10.001_bib36","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia"},{"issue":"February (3)","key":"10.1016\/j.critrevonc.2005.10.001_bib37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1702135","article-title":"Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study","volume":"25","author":"Decaudin","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"April (7)","key":"10.1016\/j.critrevonc.2005.10.001_bib38","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib39","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Antal D, Lacotte-Thierry L, et al., Rituximab\/chemotherapy induction treatment followed by high-dose therapy and autologous transplantation in patients with mantle cell lymphoma. Blood 2004;104(November):1389 [ASH annual meeting abstracts].","DOI":"10.1002\/cncr.21313"},{"issue":"March (5)","key":"10.1016\/j.critrevonc.2005.10.001_bib40","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and bone marrow transplant and autologous blood and marrow transplant registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib41","first-page":"317","article-title":"Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center","author":"Molina","year":"2000","journal-title":"Clin Transplant"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib42","unstructured":"Conde E, Marco F, Caballero D, et al., for the GEL\/TAMO Spanish Cooperative Group. Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL). In: ASH annual meeting; 2002 [abstract #2529]."},{"issue":"March (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00001622-200403000-00004","article-title":"An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Jacobsen","year":"2004","journal-title":"Curr Opin Oncol"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2005.10.001_bib44","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood."},{"issue":"August (3)","key":"10.1016\/j.critrevonc.2005.10.001_bib45","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"issue":"July (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib47","unstructured":"Geisler CH, Pedersen LB, Andersen NS, et al., Mantle cell lymphoma (MCL): increased clinical and molecular response rates adding Ara-C and rituximab to CHOP+BEAM and autologous stem cell transplantation. In: Nordic hematologic spring meeting; May 2004 [abstract P28]"},{"issue":"January (2)","key":"10.1016\/j.critrevonc.2005.10.001_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2004.05251.x","article-title":"The role of allogeneic transplantation in non-Hodgkin's lymphoma","volume":"128","author":"Peggs","year":"2005","journal-title":"Br J Haematol"},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2005.10.001_bib49","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib50","unstructured":"Kauh J, Baidas SM, Ozdemirli M, Cheson BD. Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park) 2003;17(June (6)):879\u201391, 96 [discussion 896\u20138; review erratum in: Oncology (Huntingt) 2003;17(July (7)):922]."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2005.10.001_bib51","first-page":"578","article-title":"Allogeneic bone marrow transplantation for refractory mantle cell lymphoma","volume":"79","author":"Kroger","year":"2000","journal-title":"Ann Hematol"},{"issue":"December (23)","key":"10.1016\/j.critrevonc.2005.10.001_bib52","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2005.10.001_bib53","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"issue":"December (13)","key":"10.1016\/j.critrevonc.2005.10.001_bib54","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2005.10.001_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2005.10.001_bib56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2005.10.001_bib57","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"issue":"May (9)","key":"10.1016\/j.critrevonc.2005.10.001_bib58","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib59","doi-asserted-by":"crossref","unstructured":"Oki Y, Pro B, Delpassand E, et al., A phase II study of Yttrium 90 (90Y) ibritumomab Tiuxetan (Zevalin\u00ae) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood, 2004; 104(November):2632 [ASH annual meeting abstracts].","DOI":"10.1182\/blood.V104.11.2632.2632"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib60","article-title":"Sequential Radioimmunotherapy with tositumomab\/iodine I131 tositumomab followed by CHOP chemotherapy for mantle cell lymphoma is a safe and highly effective regimen","author":"Zelenetz","year":"2005","journal-title":"Ann Oncol"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2005.10.001_bib61","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"issue":"October (5594)","key":"10.1016\/j.critrevonc.2005.10.001_bib62","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib63","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/jco.2005.23.16_suppl.2546","article-title":"Idiotype (Id) immunotherapy (IT) following high dose therapy and autologous stem cell transplant (HDT\/ASCT) in mantle cell (MC) and indolent lymphoma (IL): cellular, humoral and clinical responses","volume":"23","author":"Holman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib64","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1200\/jco.2005.23.16_suppl.6563","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"October (8)","key":"10.1016\/j.critrevonc.2005.10.001_bib65","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"issue":"August (10)","key":"10.1016\/j.critrevonc.2005.10.001_bib66","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"May (9)","key":"10.1016\/j.critrevonc.2005.10.001_bib67","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"issue":"December (23)","key":"10.1016\/j.critrevonc.2005.10.001_bib68","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Martinez","year":"2003","journal-title":"Cancer Res"},{"issue":"April (7)","key":"10.1016\/j.critrevonc.2005.10.001_bib69","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2003-06-2160","article-title":"Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis","volume":"103","author":"Thieblemont","year":"2004","journal-title":"Blood"},{"issue":"December (23)","key":"10.1016\/j.critrevonc.2005.10.001_bib70","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Martinez","year":"2003","journal-title":"Cancer Res"},{"issue":"May (9)","key":"10.1016\/j.critrevonc.2005.10.001_bib71","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1158\/1078-0432.CCR-03-0554","article-title":"High level of glutathione-S-transferase pi expression in mantle cell lymphomas","volume":"10","author":"Bennaceur-Griscelli","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"August (3)","key":"10.1016\/j.critrevonc.2005.10.001_bib72","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","article-title":"Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray","volume":"98","author":"Hofmann","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.10.001_bib73","unstructured":"Adapated from Armitage JO, Mauch PM, Harris NL, Bierman P. Non-Hodgkin's lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 6th ed. New York: Lippincott\/Williams\/Wilkins; 2001. p. 2267."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842805002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842805002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T17:34:39Z","timestamp":1707068079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842805002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S1040842805002052"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2005.10.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}